Vivo Surgical’s KLARO™ In vivo Lighting Device Provides Unparalleled Illumination of Surgical Cavities

Vivo Surgical’s KLARO™ in vivo lighting device is designed to revolutionize surgical illumination and provide a clearer view of surgical cavities. Developed in partnership with SingHealth – Singapore’s largest group of healthcare institutions – and Panasonic Lighting (Europe), this innovative LED light solution solves many of the problems associated with traditional operating theatre lighting and personal headlights.

Inadequate surgical lighting has been identified as one of the key challenges in operating theatres, particularly in complex open procedures involving deep or narrow surgical cavities. KLARO is designed specifically to eliminate this issue, giving a better view of the surgical site while eliminating the ergonomic problems associated with headtorches. The flexible LED tip offers four lighting intensities, with a compact, 4.6 mm diameter to make it easy to position during surgery, ensuring wide-angle illumination.

The single-use KLARO has been developed specifically for surgical use, offering up to four hours of consistent in vivo illumination while maintaining a safe operating temperature of below 38 °C/100°F. The FDA registered, CE certified device clips easily onto surgical drapes, with a long light strip to allow effective hands-free positioning of the light within the surgical cavity. It can also be used to transform any existing surgical retractor into a lit one using the supplied silicone retractor loops, offering seamless integration with existing instruments to minimize workflow disruption. This innovative, cost-effective solution – which is already being used in oncology, gynaecology, head and neck, and general surgery in over 20 countries – is helping to improve patient outcomes and accelerate recovery times by minimizing the size of surgical incisions, as well as relieving eye fatigue and ergonomic issues faced by surgeons.

As a clinician-driven company, Vivo Surgical is always looking to further expand the application of its novel lighting solutions, and is keen to enter into new collaborative ventures and distribution partnerships worldwide. In particular, the company is currently seeking partners with expertise in operating room consumables.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version